Monte Rosa Therapeutics (GLUE) Price to FCF (2021 - 2026)
Powered by 
Analysis
Monte Rosa Therapeutics (GLUE) Price to FCF (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Monte Rosa Therapeutics | 1.40 Bn | 771.57 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -43.00 |
| Mar 31, 2026 | -34.59 |
| Dec 31, 2025 | -29.75 |
| Sep 30, 2025 | 6.12 |
| Jun 30, 2025 | -10.18 |
| Mar 31, 2025 | -8.10 |
| Dec 31, 2024 | 3.32 |
| Sep 30, 2024 | -20.32 |
| Jun 30, 2024 | -7.70 |
| Mar 31, 2024 | -8.95 |
| Dec 31, 2023 | 10.14 |
| Sep 30, 2023 | -9.10 |
| Jun 30, 2023 | -10.67 |
| Mar 31, 2023 | -11.80 |
| Dec 31, 2022 | -12.02 |
| Sep 30, 2022 | -17.96 |
| Jun 30, 2022 | -19.58 |
| Mar 31, 2022 | -22.47 |
| Dec 31, 2021 | -29.63 |
| Sep 30, 2021 | -52.98 |